A detailed history of Rhumbline Advisers transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 75,218 shares of TRVI stock, worth $233,175. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,218
Previous 51,955 44.78%
Holding current value
$233,175
Previous $179,000 25.14%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$2.44 - $3.36 $56,761 - $78,163
23,263 Added 44.78%
75,218 $224,000
Q1 2024

May 09, 2024

BUY
$1.3 - $3.7 $638 - $1,816
491 Added 0.95%
51,955 $179,000
Q4 2023

Feb 08, 2024

SELL
$1.06 - $2.05 $2,976 - $5,756
-2,808 Reduced 5.17%
51,464 $68,000
Q3 2023

Nov 09, 2023

BUY
$2.11 - $2.47 $8,893 - $10,411
4,215 Added 8.42%
54,272 $118,000
Q2 2023

Aug 08, 2023

BUY
$1.8 - $3.44 $90,102 - $172,196
50,057 New
50,057 $119,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $181M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.